The prescription drug pricing provisions in the Inflation Reduction Act of 2022 constitute the most transformative reform to the Medicare prescription drug benefit since its inception almost 20 years ago. These provisions, including manufacturer rebates for price increases above inflation, negotiation of prices for high-spending drugs, and a cap on Part D out-of-pocket expenses, are the result of decades-long efforts to control increases in pharmaceutical spending and improve drug affordability in Medicare.
